# Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study

> **NCT00002146** · PHASE4 · COMPLETED · sponsor: **Astra USA** · enrollment: 12 (—)

## Conditions studied

- Cytomegalovirus Infections
- HIV Infections
- Hypocalcemia

## Interventions

- **DRUG:** Magnesium sulfate
- **DRUG:** Foscarnet sodium

## Key facts

- **NCT ID:** NCT00002146
- **Lead sponsor:** Astra USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 12 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002146, "Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00002146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*